A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

Lee S. Schwartzberg; Francis P. Arena; Bryan J. Bienvenu; Edward H. Kaplan; Luis H. Camacho; Luis T. Campos; J. Paul Waymack; Mary A. Tagliaferri; Michael M. Chen; Dapeng Li

首页> 外文期刊>Journal of Cancer >A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

【24h】

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

机译：康莱特注射液（KLTi）联合吉西他滨与吉西他滨治疗晚期胰腺癌的随机，开放标签，安全性和探索性研究

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background: This study was designed to assess the safety and preliminary efficacy of KLTi plus gemcitabine in patients with locally advanced or metastatic pancreatic cancer.

机译：背景：本研究旨在评估KLTi加吉西他滨在局部晚期或转移性胰腺癌患者中的安全性和初步疗效。

著录项

来源
《Journal of Cancer》 |2017年第10期|共12页
作者
Lee S. Schwartzberg; Francis P. Arena; Bryan J. Bienvenu; Edward H. Kaplan; Luis H. Camacho; Luis T. Campos; J. Paul Waymack; Mary A. Tagliaferri; Michael M. Chen; Dapeng Li;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. [J] . Gy?rgy Bodoky, Constanta Timcheva, David Robert Spigel, Investigational new drugs. . 2012,第3期

机译：II期开放标签随机研究，评估一线吉西他滨治疗失败的晚期或转移性胰腺癌患者中selumetinib（AZD6244 [ARRY-142886]）与卡培他滨的疗效和安全性。
2. Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine-cisplatin plus necitumumab versus gemcitabine-cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer [J] . Paz-Ares L., Socinski M. A., Shahidi J., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第8期

机译：EGFR表达与SQUIRE中安全性和疗效的相关性：吉西他滨-顺铂加尼西单抗与单独吉西他滨-顺铂在一线治疗IV期鳞状非癌患者中的随机，多中心，开放性，III期研究小细胞肺癌
3. Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. [J] . Spano JP, Chodkiewicz C, Maurel J, The Lancet . 2008,第9630期

机译：吉西他滨加阿昔替尼与单独吉西他滨相比在晚期胰腺癌患者中的疗效：一项开放标签的随机II期研究。
4. Dual Delivery Nanoscale Device for miR-345 and Gemcitabine Co-Delivery to Treat Pancreatic Cancer [C] . Metin Uz, Satyanaravana Rachagani, Surinder K. Batra, Society for Biomaterials annual meeting and exposition . 2017

机译：用于miR-345和吉西他滨共同递送的双递送纳米装置可治疗胰腺癌
5. Formulation, Optimization and Efficacy of Gemcitabine Loaded Thermosensitive Liposomal Nanoparticles in the Treatment of Pancreatic Cancer [D] . Affram, Kevin Osei. 2018

机译：吉西他滨负载热敏脂质体纳米颗粒的制备，优化及疗效
6. A Randomized Open-Label Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer [O] . Lee S. Schwartzberg, Francis P. Arena, Bryan J. Bienvenu, 2017

机译：康莱特注射液（KLTi）联合吉西他滨与吉西他滨治疗晚期胰腺癌的随机开放标签安全性和探索性研究
7. A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer [O] . Lee S. Schwartzberg, Francis P. Arena, Bryan J. Bienvenu, 2017

机译：Kanglaite注射（KLTI）加吉西他滨与吉西他滨的随机，开放标签，安全性和探索性疗效研究，胰腺癌患者

A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection (KLTi) plus Gemcitabine versus Gemcitabine in Patients with Advanced Pancreatic Cancer

摘要

著录项

相似文献

相关主题

期刊订阅